Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs ...

Shares are up more than 50% already this year, as the story surrounding the company’s GLP-1 drugs gets better and better.

Over the last 3 months, EPS estimates have seen 0 upward revisions and 13 downward. Revenue estimates have seen 16 upward ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients ...

Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among ...

A small tweak in the dosing regimen of Eli Lilly’s Alzheimer’s disease drug Kisunla has reduced brain swelling of patients in ...

Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

As grim as the likely loss of the U.K. market for the drug may be, Lilly is far from helpless, and the damage, while notable, might not actually drag on its growth by a noticeable amount if its ...

Eli Lilly expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News ...

Learn how to grow your wealth through smart investing strategies and financial planning in this informative article by a ...